Please wait while the formulary information is being retrieved.
TRUSELTIQ (infigratinib phosphate)
- Cholangiocarcinoma with FGFr2 fusion or rearrangement
100 mg/day (100 mg x 1) capsule
- by oral route once daily per package directions
125mg/day(100 mg x1-25mg x1) capsule
- by oral route once daily per package directions
50 mg/day (25 mg x 2) capsule
- by oral route once daily per package directions
75 mg/day (25 mg x 3) capsule
- by oral route once daily per package directions
Default screening record
- by oral route once daily per package directions
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
Contraindicated
- Child-pugh class A hepatic impairment
- Child-pugh class B hepatic impairment
- Chronic kidney disease stage 3B (moderate) GFR 30-44
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Hyperphosphatemia
- Pregnancy
- Retinal pigment epithelial detachment
Severe
Moderate
- Disease of liver
- Kidney disease with likely reduction in GFR
TRUSELTIQ (infigratinib phosphate)
- Cholangiocarcinoma with FGFr2 fusion or rearrangement
- Anemia
- Elevated serum lipase
- Hyperbilirubinemia
- Hypercalcemia
- Hyperphosphatemia
- Hypertriglyceridemia
- Hyperuricemia
- Hypoalbuminemia
- Hypokalemia
- Hyponatremia
- Hypophosphatemia
- Increased alanine transaminase
- Increased alkaline phosphatase
- Increased aspartate transaminase
- Leukopenia
- Lymphopenia
- Thrombocytopenic disorder
- Acute abdominal pain
- Alopecia
- Anorexia
- Arthralgia
- Blepharitis
- Blurred vision
- Constipation
- Diarrhea
- Dry eye
- Dry skin
- Dysgeusia
- Fatigue
- Hypertrichosis of eyelid eyelashes
- Nail disorders
- Palmar-plantar erythrodysesthesia
- Stomatitis
- Trichiasis
- Trichomegaly
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- Calciphylaxis
- Retinal pigment epithelial detachment
- Dyspepsia
- Edema
- Epistaxis
- Fever
- Headache disorder
- Nausea
- Pain in extremities
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Calcification of vascular system
- Calcinosis cutis
Less Severe
- None
Contraindicated
None
Severe Precaution
Infigratinib
No safety and efficacy. Potential risk of abnormal growth of bone and teeth.
- 1 Day – 18 Years
- No safety and efficacy. Potential risk of abnormal growth of bone and teeth.
Management or Monitoring Precaution
None
Infigratinib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Infigratinib
Mfg does not rec during tx and for 1 mo after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfg does not rec during tx and for 1 mo after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Formulary Reference Tool